DSAM Partners’s Allogene Therapeutics ALLO Stock Holding History

DSAM Partners’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.39M	Sell	54,000 -90,000	-63%	-$2.14M	0.79%	17
2021 Q2	$3.76M	Sell	144,000 -41,142	-22%	-$1.17M	0.63%	31
2021 Q1	$6.54M	Sell	185,142 -23,656	-11%	-$798K	1.21%	22
2020 Q4	$5.27M	Buy	208,798 +25,798	+14%	+$841K	0.62%	44
2020 Q3	$6.9M	Sell	183,000 -52,098	-22%	-$1.96M	1.19%	25
2020 Q2	$10.1M	Buy	235,098 +203,490	+644%	+$7.36M	2.63%	15
2020 Q1	$614K	Sell	31,608 -3,203	-9%	-$76.3K	0.15%	31
2019 Q4	$904K	Sell	34,811 -72,630	-68%	-$2M	0.21%	37
2019 Q3	$2.93M	Sell	107,441 -158,828	-60%	-$4.52M	0.55%	41
2019 Q2	$7.15M	Sell	266,269 -224,169	-46%	-$6.25M	0.89%	39
2019 Q1	$14.2M	Sell	490,438 -159,169	-25%	-$4.62M	2.05%	21
2018 Q4	$17.5M	Buy	+649,607	New	+$17.3M	3.64%	9

Other funds holding ALLO

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

DSAM Partners's ALLO Position: Q3 2021 in Review

DSAM Partners reduced its Allogene Therapeutics (ALLO) stake by 63% in Q3 2021, selling an estimated $2.14M and leaving 54,000 shares worth $1.39M. The position accounts for 0.79% of the portfolio, ranked #17.

DSAM Partners first reported a position in ALLO in Q4 2018 and has held it in 12 quarters since. The position peaked at $17.5M in Q4 2018. 169 funds tracked by Wall St. Rank hold ALLO as of Q3 2021.

DSAM Partners held 54,000 shares of Allogene Therapeutics worth $1.39M as of Q3 2021.
DSAM Partners sold 90,000 Allogene Therapeutics shares in Q3 2021, an estimated $2.14M.
Allogene Therapeutics made up 0.79% of DSAM Partners's portfolio in Q3 2021, its #17 holding.
DSAM Partners first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 12 quarters since.
DSAM Partners's Allogene Therapeutics position peaked at $17.5M in Q4 2018.
169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2021.

Based on DSAM Partners's 13F filing for Q3 2021, filed 15 Nov 2021.